Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELOXATIN vs EPIOXA HD/EPIOXA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.
Oxaliplatin undergoes nonenzymatic biotransformation to active platinum derivatives that form inter- and intrastrand crosslinks in DNA, inhibiting DNA replication and transcription.
Adjuvant treatment of stage III colon cancer after complete resection of primary tumor,Treatment of advanced colorectal cancer in combination with 5-fluorouracil and leucovorin
Adjuvant treatment of stage III colon cancer after complete resection of primary tumor,Advanced colorectal cancer in combination with fluorouracil and leucovorin
85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).
EPIOXA HD: 100 mg/m² IV over 2 hours every 2 weeks. EPIOXA KIT: 100 mg/m² IV over 2 hours every 2 weeks.
Terminal half-life of ultrafilterable platinum: ~10-27 hours (mean ~14 hours); total platinum: ~40-50 hours. Clinical context: prolonged exposure due to tissue binding.
Terminal elimination half-life is approximately 0.7-1.1 hours (42-66 minutes) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Oxaliplatin undergoes rapid non-enzymatic biotransformation in plasma and tissues to form active platinum derivatives, primarily via displacement of the oxalate ligand. Minimal hepatic metabolism; elimination is predominantly renal.
Nonenzymatic biotransformation; extensive tissue distribution; mainly eliminated via renal excretion.
Renal: ~54% of platinum excreted in urine within 48 hours; fecal: small amount (<2%); biliary excretion is minimal.
Primarily renal excretion; 70-80% of the dose is eliminated unchanged in urine within 48 hours; biliary/fecal excretion accounts for less than 10%.
Platinum binds >90% to plasma proteins, mainly albumin and gamma-globulins; irreversible binding.
Low protein binding; approximately 10-20% bound to plasma proteins, primarily albumin.
Vd of ultrafilterable platinum: ~0.4-0.6 L/kg; total platinum: ~4-6 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 0.1-0.25 L/kg, indicating distribution primarily in extracellular fluid; clinically, this suggests limited tissue penetration.
Oral: Not bioavailable (unstable in GI tract); IV: 100%.
Oral bioavailability is negligible (<1%); therefore, the drug is administered exclusively via intravenous route.
Cr Cl ≥60 m L/min: No adjustment; Cr Cl 50-59 m L/min: No adjustment; Cr Cl 40-49 m L/min: Administer 85 mg/m2, but no data for 130 mg/m2; Cr Cl 30-39 m L/min: Administer 85 mg/m2 with caution, no data for 130 mg/m2; Cr Cl 20-29 m L/min: Administer 85 mg/m2 with extreme caution, no data for 130 mg/m2; Cr Cl <20 m L/min: Not recommended.
Cr Cl <30 m L/min: contraindicated. Cr Cl 30-50 m L/min: reduce dose to 75 mg/m². Cr Cl >50 m L/min: no adjustment.
Child-Pugh A: No adjustment required; Child-Pugh B: No adjustment required; Child-Pugh C: Use with caution; no specific dose reduction defined.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 75 mg/m². Child-Pugh C: not recommended.
Not approved for pediatric use. No established dosing guidelines.
Safety and efficacy not established in pediatric patients; use not recommended.
No specific dose adjustment recommended based on age alone; monitor renal function and adjust according to calculated creatinine clearance.
No specific dose adjustment; monitor renal function and toxicity closely.
Anaphylactic-like reactions to oxaliplatin have been reported, which may occur within minutes of administration and require immediate discontinuation and symptomatic treatment. Oxaliplatin should be discontinued if severe hypersensitivity occurs.
Anaphylactic reactions have been reported and may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines should be available.
Hypersensitivity reactions (including anaphylaxis) have been reported and may be life-threatening. Discontinue permanently if severe reaction occurs.,Peripheral neuropathy, which may be acute (reversible) or chronic (persistent), is dose-limiting and requires dose adjustment or discontinuation.,Hepatotoxicity, including hepatic sinusoidal obstruction syndrome, has been reported. Monitor liver function.,Pulmonary toxicity, including pulmonary fibrosis, has been observed. Discontinue if interstitial lung disease is suspected.,Bleeding risk due to thrombocytopenia; monitor platelet counts.,Rhabdomyolysis has been reported; monitor for muscle pain/weakness.,Post-marketing reports of reversible posterior leukoencephalopathy syndrome (RPLS); discontinue if symptoms occur.
Peripheral neuropathy, acute and chronic; pulmonary fibrosis; hepatic toxicity; renal impairment; pregnancy category D; myelosuppression; extravasation.
History of severe hypersensitivity to oxaliplatin or any components of the formulation,Severe renal impairment (creatinine clearance <30 m L/min),Bone marrow suppression with baseline neutrophil count <1.5 × 10^9/L or platelet count <75 × 10^9/L,Pregnancy (can cause fetal harm)
History of severe hypersensitivity to oxaliplatin or other platinum compounds; severe renal impairment (Cr Cl <30 m L/min).
Avoid cold food and beverages for 48 hours post-infusion to prevent acute neuropathy exacerbation. No known specific food-drug interactions; however, avoid grapefruit juice if taking CYP3A4-metabolized drugs (not oxaliplatin itself). Maintain adequate hydration; no restriction with normal meals.
Avoid cold foods and beverages for 48 hours post-infusion to reduce risk of cold-induced paresthesias. No specific food-drug interactions known; maintain adequate nutrition.
Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of action (DNA cross-linking). Use during pregnancy is contraindicated unless maternal benefit outweighs risk. First trimester exposure carries highest risk of major malformations; second and third trimester exposure may cause fetal growth restriction, myelosuppression, and neurotoxicity.
EPIOXA HD/EPIOXA KIT contains epirubicin, an anthracycline cytotoxic agent classified as FDA Pregnancy Category D. First trimester: high risk of embryotoxicity and teratogenicity; use contraindicated due to potential for spontaneous abortion and major congenital malformations. Second and third trimesters: risk of fetal myelosuppression, intrauterine growth restriction (IUGR), and premature delivery. Avoid use unless maternal benefit outweighs fetal risk.
It is unknown whether oxaliplatin or its metabolites are excreted in human milk. Due to potential serious adverse reactions in nursing infants, including myelosuppression and neurotoxicity, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. No M/P ratio data available.
Epirubicin is excreted in human breast milk. The M/P ratio is not determined. Breastfeeding is contraindicated during therapy and for at least 1 month after last dose due to potential for severe adverse effects in the nursing infant (e.g., immunosuppression, neutropenia, cardiotoxicity).
No established dosing adjustments for pregnancy. Physiological changes (increased volume of distribution, altered hepatic metabolism, enhanced renal clearance) may reduce drug exposure. However, due to teratogenicity, use is not recommended. If deemed necessary, therapeutic drug monitoring is not standard and dose adjustments should be made based on clinical response and toxicity, with cautious monitoring of side effects.
No standard dosing adjustments are established for pregnancy due to lack of safety data. However, pregnancy-induced pharmacokinetic changes (e.g., increased plasma volume, altered hepatic metabolism) may necessitate dose individualization. Routine therapeutic drug monitoring is not performed. Treatment in pregnancy is generally avoided; if essential, use the lowest effective dose with close maternal and fetal monitoring.
Eloxatin (oxaliplatin) causes acute and chronic peripheral neuropathy; acute symptoms are triggered by cold exposure. Premedicate with antiemetics (e.g., aprepitant, dexamethasone, 5-HT3 antagonist) and avoid cold drinks or ice during infusion and for 48 hours thereafter. Monitor for laryngopharyngeal dysesthesia with cold exposure. Do not use aluminum-containing needles or IV sets as they degrade platinum compounds. Oxaliplatin is not compatible with chloride-containing solutions; dilute only in 5% dextrose in water. Assess renal function and reduce dose if Cr Cl < 30 m L/min.
EPIOXA (oxaliplatin) is a platinum-based antineoplastic agent used in colorectal cancer. Administer via IV infusion over 2-6 hours; pre-hydration not required but antiemetics recommended. Acute dysesthesias exacerbated by cold exposure; instruct patient to avoid cold drinks, ice, and cold environments during and for 48 hours after infusion. Monitor for peripheral neuropathy, which may be cumulative and dose-limiting. Co-administer with leucovorin and 5-FU as part of FOLFOX regimen.
Avoid cold drinks, ice, and cold temperatures during and for 2 days after infusion to prevent severe tingling or throat discomfort.,Report any numbness, tingling, or pain in hands/feet that interferes with daily activities or does not improve between cycles.,Take anti-nausea medications as prescribed before each infusion; call your doctor if vomiting persists.,Watch for signs of allergic reaction: rash, hives, difficulty breathing, swelling of face/lips/tongue.,Do not touch infusion tubing or eat ice chips during treatment due to cold sensitivity.
Avoid cold foods, drinks, and ice for 2-3 days after treatment to prevent throat and hand discomfort.,Report persistent numbness, tingling, or pain in hands/feet; may require dose adjustment.,Take antiemetics as prescribed to prevent nausea/vomiting.,Notify healthcare provider immediately if you experience difficulty breathing or facial swelling.,Use contraception for up to 9 months after treatment ends; avoid breastfeeding.
No interactions on record
No interactions on record
Common clinical questions about ELOXATIN vs EPIOXA HD/EPIOXA KIT, answered by our medical review team.
ELOXATIN is a Platinum-Based Antineoplastic that works by Oxaliplatin undergoes non-enzymatic biotransformation to form platinum-DNA adducts, leading to inhibition of DNA replication and transcription, and ultimately cell death. It is a third-generation platinum-based alkylating agent.. EPIOXA HD/EPIOXA KIT is a Platinum-Based Antineoplastic that works by Oxaliplatin undergoes nonenzymatic biotransformation to active platinum derivatives that form inter- and intrastrand crosslinks in DNA, inhibiting DNA replication and transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELOXATIN and EPIOXA HD/EPIOXA KIT depend on the specific clinical indication. These are both Platinum-Based Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELOXATIN is: 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks (adjuvant); 85 mg/m2 IV over 2 hours on day 1, repeated every 2 weeks or 130 mg/m2 IV over 2 hours on day 1, repeated every 3 weeks (advanced disease).. The standard adult dose of EPIOXA HD/EPIOXA KIT is: EPIOXA HD: 100 mg/m² IV over 2 hours every 2 weeks. EPIOXA KIT: 100 mg/m² IV over 2 hours every 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELOXATIN and EPIOXA HD/EPIOXA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELOXATIN is classified as Category C. Eloxatin (oxaliplatin) is a platinum-based antineoplastic agent classified as FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and its mechanism of. EPIOXA HD/EPIOXA KIT is classified as Category C. EPIOXA HD/EPIOXA KIT contains epirubicin, an anthracycline cytotoxic agent classified as FDA Pregnancy Category D. First trimester: high risk of embryotoxicity and teratogenicity; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.